| Nov 15 |
AZTR: Planning 2nd Site for ATR-12 Trial
|
| Nov 13 |
Azitra GAAP EPS of -$0.17
|
| Nov 12 |
Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates
|
| Oct 29 |
Azitra to Present at BIO-Europe 2024
|
| Sep 24 |
Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress
|
| Sep 18 |
Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors
|
| Sep 6 |
Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 28 |
Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome
|
| Aug 23 |
AZTR: First ATR-12 Patient Screened
|
| Aug 22 |
Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors
|
